ArticleBMC complementary medicine and therapies2025
Efficacy and safety of tangweian recipe in the treatment of diabetic gastroparesis: a protocol for a non-inferiority, double-blind, active drug, randomized controlled clinical trial.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05720442 (Efficacy Assessment of Chinese Herbal Medicine Tangweian Recipe Treating Participants With Diabetic Gastroenteropathy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy Assessment of Chinese Herbal Medicine Tangweian Recipe Treating Participants With Diabetic Gastroenteropathy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDiabetic Gastroparesis (DGP) is a syndrome characterized by delayed gastric emptying and upper gastrointestinal symptoms. As the incidence of diabetes mellitus continues to increase, so does the incidence of DGP, which severely affects the fasting plasma glucose (FPG) control and quality of life of diabetic patients. Tangweian recipe (TWA) is an effective recipe for treating DGP with spleen and stomach disharmony evidence. Previous clinical trials have provided preliminary verification of the effectiveness of TWA in treating DGP. However, high-quality clinical evidence supporting this treatment is lacking. Therefore, the purpose of this study is to conduct a clinical randomized controlled trial to obtain conclusive evidence regarding the effectiveness of TWA. METHODS AND ANALYSIS: This study is a randomized, positive, parallel controlled clinical trial in patients with DGP. A total of 72 patients were recruited and randomized using a random number method to receive either TWA combined with mosapride or mosapride alone for a treatment period of 4 weeks. PRIMARY OUTCOME: The American neurogastroenterology and motility society gastroparesis cardinal symptom index-daily diary (ANMS GCSI-DD). SECONDARY OUTCOMES: Changes in FPG, weight, body mass index (BMI), gastric emptying rate testing, Wexner constipation scores, traditional chinese medicine (TCM) evidence scores and quality of life (QOL) assessment before and after treatment. In addition, we will also perform a safety analysis.
trial registrationThe study was registered at ClinicalTrials.gov (NCT05720442) on February 9,2023 ( https://clinicaltrials.gov/study/NCT05720442 ), and the registration center is Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.